|
Corporate Profile
SIGA designs and develops novel countermeasures
to prevent and treat serious infectious diseases, with an emphasis
on biological warfare defense. SIGA’s leading program is ST-246,
an oral therapeutic agent active against orthopoxviruses including
smallpox. Additional programs target arenaviruses such as Lassa
fever, filoviruses such as Ebola and Marburg, flaviviruses such
as Dengue fever, and other category A diseases.
The company has developed a proprietary discovery platform that can be applied to many pathogens. With strong working relationships with the National Institutes of Health (NIH), the Department of Defense, and other federal agencies, SIGA believes it is competitive with all other biodefense drug development companies today.
|
REPORTS EARNINGS |
|
Access denied for user 'apache'@'localhost' (using password: NO)
| |
